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Background Mucosal melanomas (MM) represent a
heterogeneous tumour population that exhibits site-
specific molecular profiles.
Aims In a multicentre retrospective study, we
investigated KIT aberrations in primary anorectal (AR)
melanomas compared with melanoma metastatic to the
gastrointestinal (GI) tract.
Methods Primary AR MM (n=31) and GI metastatic
melanoma (n=27) were studied for KIT mutations on
exons 11, 13, 17 and 18 by high-resolution melting
analysis, direct sequencing and c-KIT expression by
immunohistochemistry. Selected cases were also
investigated for increased KIT gene copy number by
fluorescent in situ hybridisation.
Results Functional KIT mutations were demonstrated in
11/31 (35.5%) of AR melanomas and in 1/26 (3.8%) of
GI melanoma metastases (p=0.004). A significant
difference emerged between primary and metastatic MM
with regards to KIT-positive immunostaining (p=0.002).
Immunohistochemical c-KIT protein overexpression did not
correlate with KIT mutational status. Increased KIT copy
number was demonstrated in 5/20 AR primary cases.
Conclusions The rate of functional mutations in KIT is
significantly higher in AR MM than in GI metastatic
melanoma. KIT protein overexpression does not correlate
with KIT mutations and cannot be used for screening
purposes. Recognising the molecular heterogeneity of
MM helps to identify patients who require a different
therapeutic approach.
INTRODUCTION
Melanomas of the gastrointestinal (GI) tract are rare
neoplasms, often representing metastatic disease
located in the small bowel.1 In autopsy series, 43.5%–
60% of patients who die of cutaneous melanoma
have GI metastases.2–4 Nevertheless, mainly being
asymptomatic, <5% of metastases to the GI tract are
clinically diagnosed during the patient’s lifetime.1
Primary mucosal melanomas (MM) account for
approximately 1.3% of all melanomas.5 Anorectal
(AR) melanomas constitute 23.8% of primary MM,
whereas head and neck region, the female genital
tract and the urinary tract represent 55.4%, 18% and
2.8% of cases, respectively.5 Although rarely, MM in
the GI tract have been found in the oesophagus,
stomach, small and large bowel.6 7
GI melanomas are associated with a severe prog-
nosis regardless of the therapy employed.6 For
current and more effective personalised therapies,
incorporation of genetic signatures into the mor-
phological classification of melanoma is manda-
tory.8 9 In recent years, the use of kinase inhibitors
in patients with melanoma with documented KIT
mutations has shown promising results.10–16
The reported frequency of KIT mutations in
MM varies between 5.4% and 38% (mean 17.6%;
median 17%).17–32 Frequent association between
KIT mutations and overexpression of c-KIT protein
has been reported,17 18 20–22 25 26 29 however, data
are still conflicting.15 19 30–33
To identify the molecular signature of primary
AR melanomas, we investigated KIT aberrations by
evaluating KIT mutational status and c-KIT protein
immunohistochemical expression in a series of 31
primary AR melanomas compared with 27 cases of
cutaneous melanoma metastatic to the GI tract.
Selected AR cases were also tested for KIT gene




We searched the patient database at the Pathological
Anatomy Units belonging to the Tumour Institute of
Tuscany (ITT) network (Italy), at the Department of
Pathology, National Cancer Institute ‘Fondazione
G. Pascale’ of Naples (Italy) and at the Department
of Oncology and Haematology, Papa Giovanni XXIII
Hospital of Bergamo (Italy), for cases diagnosed
between 1991 and 2013 as primary or metastatic
melanoma involving the GI tract. Institutional
Review Board was informed and consented in the
study. Histological sections were reviewed by two
pathologists independently to confirm the diagnosis.
In each case, a representative formalin-fixed,
paraffin-embedded block was selected and used for
immunohistochemistry as well as for molecular
studies. Since exons 11, 13, 17 and 18 are described
as common mutation sites of KIT in melanomas,17 22
the study focused on the detection of somatic muta-
tions in these exons. FISH analysis was performed in
seven cases to exclude the presence of t(12;22)(q13;
q12) translocation (r/o soft parts/clear cell sarcoma).
FISH was also employed for KIT amplification ana-
lyses and high-resolution melting analysis (HRMA)
and Sanger sequencing were used for mutational
testing. For detailed description of immunohisto-
chemistry, FISH and gene mutation analysis, see
online supplementary file 1.
Evaluation and statistics
Immunohistochemical stains were evaluated for the
percentage of labelled cells and the intensity of
immunoreactivity according to the grading criteria
suggested by Alexis and coauthors.34 The amount of
immunopositive cells was reported as follows: 0, no
staining or weak staining in individual cells; 1+,
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spotty weak staining of groups of cells; 2+, diffuse weak staining
or moderate staining of up to 50% of cells; 3+, moderate stain-
ing of >50% to 75% of cells; 4+, moderate to strong staining of
>75% of cells. For statistical purposes, we then divided cases
into two groups based on KIT immunohistochemical expression:
melanomas overexpressing KIT (scored as 3+ or 4+) and mela-
nomas with low/absent KIT expression (tumours scored as
0/1+/2+).
We accessed the Sanger COSMIC (Catalogue of Somatic
Mutations in Cancer) databank (http://www.sanger.ac.uk/
genetics/CGP/cosmic/) in order to compare previously reported
KIT mutations with our results. We have taken into account
only KIT functional mutations that are known/expected to affect
the protein phenotype.
The software SPSS for Windows V.17.0 (SPSS, Chicago,
Illinois, USA) was used for statistical analysis. A two-tailed
Pearson’s χ2 test was performed, and a value of p≤0.05 was
considered statistically significant.
RESULTS
Patient characteristics and follow-up data
Among patients affected by primary AR melanomas (n=31), age
ranged from 56 to 89 years (median 73 years) and included
64.5% (20/31) women and 35.5% (11/31) men. Mean
follow-up period was 18.3 months (data were available for 28/
31 patients). Anatomical sites of GI metastases (n=27) included
small bowel (n=15), large bowel (n=5), stomach (n=3) and
oesophagus (n=1). Three patients presented with multiple
lesions, comprising different and/or distant GI organs and the
omentum. Age ranged from 26 to 82 years (median 63 years)
and included 66.7% (18/27) men and 33.3% (9/27) women.
Mean follow-up period was 23.5 months (data were available in
21/27 cases).
Histological features of AR melanomas
AR melanomas generally presented as exophytic, diffusely ulcer-
ated lesions. Median tumour size was 3.3 cm (range 0.4–7 cm).
Sixteen AR melanomas (16/31; 51.6%) were amelanotic;
melanin pigment, at least focally, was present in the remaining
cases. Epithelioid melanomas represented the most common
subtype (17/31; 54.8%), whereas epithelioid and spindle (n=11;
35.5%) and spindle (n=3; 9.7%) melanomas were less frequently
encountered. Primary AR melanomas were all invasive and
Breslow thickness ranged from 5 to 15 mm (mean 10.5 mm)
with a mitotic index varying from 6 to 30 mitoses/mm2 (mean
11.9 mitoses/mm2). Of the nine surgical resection specimens, five
were confined to the visceral wall, whereas extension to the peri-
visceral fat was observed in the remaining cases.
Immunohistochemical results
Overall, c-KIT overexpression (score 3+/4+) was observed in
18/31 (58.1%) primary AR melanomas and in 5/27 (18.5%)
metastatic cases. Absent or low c-KIT expression (score 0, 1+,
2+) was demonstrated in 13/31 (41.9%) primary tumours and
in 22/27 (81.5%) metastatic cases (figure 1). This difference was
statistically significant (p=0.002).
Mutational analysis results
Mutational analysis of the KIT gene was performed in all
primary AR melanomas and in 26/27 metastatic cases.
In AR melanomas, four cases were found to have mutations
on exon 11: the L576P mutation (n=3) and a three-nucleotide
deletion p.Y578_D579del (n=1), previously reported in the
Sanger COSMIC databank (figure 2). Seven cases showed muta-
tions on exon 17: the p.Y823D mutation (n=6) and the silent
p.R804R mutation (n=1). On exon 13, the p.K642R mutation
was identified in one case.
Among metastatic melanomas, one of three gastric cases har-
boured the p.Y823D mutation on exon 17, whereas in a small
bowel MM a silent mutation (p.V555V) on exon 11 was
detected. No genetic alterations were detected on exon 13.
Exon 18 resulted wild-type in all 57 MM cases.
A statistically significant difference emerged in the frequency
of functional KIT mutations (missense and frameshift mutations)
between primary and metastatic cases (11/31, 35.5% vs 1/26,
3.8%, p=0.004).
Genotype/phenotype correlation
Among the 22 samples with immunohistochemical score 3+ or
4+, 45.5% (10/22) harboured functional mutations, whereas
54.5% (12/22) were KIT wild-type. In contrast, among the 35
samples with immunohistochemical score 0/ 1+/ 2+, only 5.7%
(2/35) harboured the p.Y823D mutation on exon 17, whereas
33/35 (94.3%) were KITwild-type.
KIT copy number increase
Extra copies of KITwere found in 5/20 AR melanomas (25%).
These tumours showed c-KIT overexpression, score 3+ (n=1)
and 4+ (n=4). At sequencing analysis, four cases were KITwild-
type, whereas one also harboured the p.Y823D mutation
(figure 3).
DISCUSSION
The most striking result of the present study is that the fre-
quency of functional KIT gene mutations is significantly higher
in AR MM than melanomas metastatic to the GI tract (35.5%
vs 3.8%, p=0.004). Previous studies reported a range of KIT
mutations in MM of the GI tract between 5.4% and 38%
Figure 1 (A) Diffuse, strong immunohistochemical expression of c-KIT in a case of primary anorectal melanoma (original magnification ×10);
(B) a case of cutaneous melanoma metastatic to the small bowel showing weak c-KIT immunostaining (original magnification ×20); (C) lack of
c-KIT-positive cells in a metastatic melanoma of the small bowel (original magnification ×10).
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(median 17%).17–32 Regarding AR MM the reported frequency
varied between 0% and 67% (median 15%).18 20 23 24 26 30 32
In our series, the frequency of mutated samples was higher
than the median frequency previously acknowledged. The wide
range of KIT frequencies so far reported in AR melanomas may
reflect different inclusion criteria and small sample size bias,
with number of cases varying between 2 and 40 cases (mean
17.4; median 21).18 20 23 24 26 30 32
Differentiating primary from metastatic GI melanomas can be
challenging.6 7 Suggestive features of the primary nature of GI
melanoma include lack of concurrent or previous removal of a
melanoma or atypical melanotic lesion from the skin, lack of
other organ involvement and in situ changes in the overlying or
adjacent GI epithelium.35 Differential diagnosis of MM includes
clear cell sarcoma and GIST. Clinical presentation, appropriate
immunohistochemistry and molecular biology tests should be
considered to avoid diagnostic misinterpretation with relevant
therapeutic implications.
To the best of our knowledge, this is one of the largest series
of primary and metastatic GI tract melanomas so far reported.
Among the 11 AR MM, three tumours harboured the L576P
mutation on exon 11. These patients were treated with imatinib
and are still alive and with response after 10, 12 and
14 months, respectively. In our series, seven patients harboured
the p.Y823D mutation, which appears to determine a loop alter-
ation in the c-KIT protein that, in turn, may predict resistance
to imatinib in GIST.36 No similar data have been reported in in
vitro or in in vivo melanoma models. Recent data suggest that
flumatinib, an inhibitor of BCR-ABL/PDGFR/KIT, has superior
efficacy compared with imatinib or sunitinib against GIST cell
Figure 2 Upper row: schematic representation of the preAmp-high-resolution melting analysis (HRMA) methodological approach. (A) Absence of
specific amplification on KIT exon 17 after a direct PCR; (B) specific amplification on KIT exon 17 demonstrated after the preAmp-HRMA protocol,
which includes a second amplification with internal primers (tested sample: red line; positive control: green line; direct PCR: black line). Lower row:
electropherograms of mutated samples. (C) K642R mutation detected in the exon 13, consequently to an AAA>AGA substitution; (D) CGG>CGA
substitution responsible of the R804R silent mutation; (E) the p.Y823D mutation caused by a TAT>GAT substitution.
Figure 3 (A) A case of anorectal melanoma resulted wild-type for KIT (original magnification ×20); (B) strong and diffuse c-KIT
immunohistochemical staining, original magnification 40×; (C) fluorescent in situ hybridisation analysis for KIT showing an increase in fused signals
for probes to 4q12 (LSI 4q12 Tri-Colour Rearrangement Probe—Vysis-Abbott Molecular).
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lines with the secondary mutation p.Y823D.36 Since KIT inhibi-
tors are target-oriented agents, we could hypothesise that drugs
overcoming loop mutations may be an effective therapy in MM
with KIT mutations conferring imatinib resistance.16 37 38
Overall, 12/45 (26.7%) KITwild-type tumours showed a high
percentage of c-KIT strongly positive cells (scores 3+, 4+) at
immunohistochemical analysis. Among these, four cases showed
an increased KIT copy number at FISH analysis. One AR melan-
oma with increased KIT copy number also presented the p.
Y823D mutation on exon 17. KIT increased copy number and
amplification have been reported in primary MM, either with
or without mutations.17–19 26–28 30 31 It has been suggested that
KIT gene amplification is an unusual event in AR melanomas,
although modest increase in KIT copy number can be seen in up
to one-third of cases.18 19 Increased KIT copy number,
co-overexpression of cyclin-dependent kinase 4 and KIT, epigen-
etic mechanisms and autocrine/paracrine stimulation of KIT
receptor have all been proposed to explain c-KIT protein
expression in KIT wild-type cases.17 22 28 39–41 However, KIT
wild-type amplified tumours do not appear to be sensitive to
tyrosine kinase inhibitors.37 42
Overall, our results suggest that immunohistochemical c-KIT
overexpression does not correlate with KIT functional mutation.
Although KIT mutations rarely occur in the absence of c-KIT
protein expression,18 22 CD117-negative staining cannot reliably
rule out the presence of the mutation.15 30–33
In summary, our data suggest that the incidence of activating
KIT mutations is higher in AR MM than in melanoma metasta-
sising to the GI tract. KIT-mutated MM are susceptible for
therapy with specific kinase inhibitors and the recognition of
the molecular heterogeneity of these tumours may help to iden-
tify patients requiring a different therapeutic approach.
Take home messages
▸ A significant number of anorectal (AR) mucosal melanomas
(MM) harbour KIT activating mutations.
▸ Immunohistochemical c-KIT overexpression does not
correlate with the presence of KIT activating mutations.
▸ In AR MM, the spectrum of KIT genetic aberrations is wide
and specific KIT mutations may have different sensitivity to
c-KIT inhibition.
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